GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (FRA:DVL) » Definitions » Research & Development

Alliance Pharma (FRA:DVL) Research & Development : €0.0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Alliance Pharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Alliance Pharma's Research & Development for the six months ended in Jun. 2024 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €0.0 Mil.


Alliance Pharma Research & Development Historical Data

The historical data trend for Alliance Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Research & Development Chart

Alliance Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alliance Pharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alliance Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma  (FRA:DVL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Alliance Pharma Research & Development Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. The company generates the majority of its revenue from the Consumer Healthcare segment. The products of the company include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, Fazol, and others. Geographically, the company derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma Headlines

No Headlines